Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus johnsonii ncc 533
- Development stage
- Unknown
- Lead developer
- Nestlé
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Topical
01
Overview
Lactobacillus johnsonii NCC 533 is a probiotic intestinal bacterium extensively studied for its probiotic activities, including pathogen inhibition, epithelial cell attachment, and immunomodulation[9][5][3]. It is used in commercial products such as the yogurt-like dairy product LC1 by Nestlé to support gut health and strengthen natural defenses[3][5]. The strain has been shown to persist longer in the gut compared to other strains of L. johnsonii due to specific genetic adaptations[2]. Its mechanisms include production of lactic acid and bacteriocins, hydrogen peroxide generation with antimicrobial effects against pathogens like Salmonella enterica serovar Typhimurium SL1344[7][8], synthesis of inulin-type fructans via an inulosucrase enzyme (InuJ)[3][10], and modulation of host immune responses such as reduction of H. pylori-related inflammation and promotion of antimicrobial peptide expression on skin when applied topically[5][6].
- Brand names
- LC1LC-1LC 1
- Other names
- Lactobacillus johnsonii NCC 533L. johnsonii NCC 533La1La-1La 1
02
Targets
Shigella spp. (Shigella species)
Beyond the preview
Go deeper on lactobacillus johnsonii ncc 533.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus johnsonii ncc 533.